Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS ONOV
BioNovelus, Inc. Ready to Ship Eco-Friendly Fungicide, CR-10, to Fight Coffee Rust in Costa Rica!
Jun 22, 2016
OTC Disclosure & News Service
-
Phoenix, June 22, 2016 (GLOBE NEWSWIRE) -- BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce that four thousand (4,000) bottles of its biodegradable fungicide, CR-10, the answer to killing coffee rust, has been manufactured for delivery to Costa Rica.
Mr. Jean Ekobo, President/CEO of BioNovelus, Inc., says, "This CR-10 allotment is slotted for ongoing tests with our partners, as well as to satisfy pre-orders. This represents a huge milestone for our Company and its shareholders, because it brings BioNovelus closer to Revenue Stage."
“Our tests have shown that one bottle of CR-10 will treat one hectare of a coffee plantation. Coffee farmers will need 3 applications per growing season to effectively and safely kill the coffee rust.”
The chart below shows the market potential for countries that have coffee rust and are perfectly suited for BioNovelus CR-10. Costa Rica, with only its 93,800 hectares of coffee plantations, has consumed 257,667 liters (or bottles) of chemical fungicide to try to control the coffee leaf rust in 2015. Central America, along with Mexico and Colombia, represent a substantial market for BioNovelus non-toxic fungicide CR-10.
COUNTRY HECTARES OF
COFFEE PLANTATIONS
Colombia
980,000 ha
Mexico
680,000 ha
Honduras 282,000 ha
Guatemala 276,500 ha
El Salvador 152,200 ha
Nicaragua 126,200 ha
Costa Rica 93,800 ha
TOTAL 2,591,200 hectares
http://www.otcmarkets.com/stock/ONOV/news
NEWS ONOV
BioNovelus, Inc. Ready to Ship Eco-Friendly Fungicide, CR-10, to Fight Coffee Rust in Costa Rica!
Jun 22, 2016
OTC Disclosure & News Service
-
Phoenix, June 22, 2016 (GLOBE NEWSWIRE) -- BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce that four thousand (4,000) bottles of its biodegradable fungicide, CR-10, the answer to killing coffee rust, has been manufactured for delivery to Costa Rica.
Mr. Jean Ekobo, President/CEO of BioNovelus, Inc., says, "This CR-10 allotment is slotted for ongoing tests with our partners, as well as to satisfy pre-orders. This represents a huge milestone for our Company and its shareholders, because it brings BioNovelus closer to Revenue Stage."
“Our tests have shown that one bottle of CR-10 will treat one hectare of a coffee plantation. Coffee farmers will need 3 applications per growing season to effectively and safely kill the coffee rust.”
The chart below shows the market potential for countries that have coffee rust and are perfectly suited for BioNovelus CR-10. Costa Rica, with only its 93,800 hectares of coffee plantations, has consumed 257,667 liters (or bottles) of chemical fungicide to try to control the coffee leaf rust in 2015. Central America, along with Mexico and Colombia, represent a substantial market for BioNovelus non-toxic fungicide CR-10.
COUNTRY HECTARES OF
COFFEE PLANTATIONS
Colombia
980,000 ha
Mexico
680,000 ha
Honduras 282,000 ha
Guatemala 276,500 ha
El Salvador 152,200 ha
Nicaragua 126,200 ha
Costa Rica 93,800 ha
TOTAL 2,591,200 hectares
http://www.otcmarkets.com/stock/ONOV/news
strong news - Phoenix, June 22, 2016 (GLOBE NEWSWIRE) -- BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce that four thousand (4,000) bottles of its biodegradable fungicide, CR-10, the answer to killing coffee rust, has been manufactured for delivery to Costa Rica.
$DRAM $150M merger with a gold company
http://broadstreetalerts.com/wp-content/uploads/2016/06/DRAM-8-k.pdf
$DRAM $150M merger with a gold company
http://broadstreetalerts.com/wp-content/uploads/2016/06/DRAM-8-k.pdf
$DRAM $150M merger with a gold company
http://broadstreetalerts.com/wp-content/uploads/2016/06/DRAM-8-k.pdf
$DRAM $150M merger with a gold company
http://broadstreetalerts.com/wp-content/uploads/2016/06/DRAM-8-k.pdf
DRAM merger $1.53 AH
Change
+0.13 +9.29%
Volume
211,806
DRAM merger $1.53 AH
Change
+0.13 +9.29%
Volume
211,806
DRAM merger $1.53 AH
Change
+0.13 +9.29%
Volume
211,806
DRAM merger $1.53 AH
Change
+0.13 +9.29%
Volume
211,806
$1.9 billion proposal to combat Zika
President Barack Obama on Friday urged lawmakers to take up his $1.9 billion proposal to combat Zika, suggesting anything less would leave the U.S. vulnerable to the mosquito-borne virus that causes birth defects.
http://edition.cnn.com/2016/05/20/politics/obama-zika-briefing/index.html
May 31, 2016 PositiveID Adds Benedikt von Braunmuhl to its Board of Advisors
Mr. von Braunmuhl has more than 20 years of experience with global healthcare companies, and will assist the Company’s efforts to commercialize Firefly Dx to detect Zika and other pathogens
DELRAY BEACH, Fla., May 31, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has added international healthcare and business development executive Benedikt von Braunmühl to its Board of Advisors.
Von Braunmühl is currently Chairman of the Board of Directors of PathoQuest, a next generation molecular diagnostics company with a unique approach in infectious diseases diagnostics. In addition, he acts as advisor of the healthcare practice group at Clairfield International, a mergers and acquisitions advisory firm for global mid-market transactions with 39 offices in 23 countries. He has held several high-profile healthcare consulting and advisory roles for companies across the globe supporting geographic expansion, business development, and mergers and acquisitions projects. Von Braunmühl previously was Senior Vice President - Global Commercial Operations of Qiagen NV, a leading European biotechnology company active in molecular diagnostics and life science markets.
“We are honored to add Benedikt to our Board of Advisors to raise awareness of our product offerings and our technical and scientific expertise among potential partners,” said William J. Caragol, Chairman and CEO of PositiveID. “We believe his strategic insights and broad industry relationships, which align closely with our business, will be valuable in helping us reach the next stage in our growth.”
Mr. von Braunmühl started his 25-year healthcare career at AstaMedica and has held various marketing and sales positions in the healthcare industry as well as in investment banking. He holds a Bachelor Degree in Business Administration from the Graduate School of Business Administration in Zurich, Switzerland.
% of Vol Shorted very low
http://otcshortreport.com/index.php?index=psid#.U6Z2sOmTErG
Vast Firefly Dx market opportunity: global molecular diagnostics market estimated at $45B by 2020; global PCR market estimated at $13B by 2020; food safety testing projected to reach $19B by 2018
PositiveID’s E-N-G Mobile Systems Ships Mobile Lab in Excess of $700,000 to Customer
E-N-G has delivered more than 400 mobile labs to domestic and international customers
DELRAY BEACH, Fla., April 25, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its E-N-G Mobile Systems (“ENG”) subsidiary has shipped a 40-foot BSL-3 compliant mobile laboratory valued in excess of $700,000. Due to the nature and location of the mobile lab, the customer is being kept confidential. Since its inception, ENG, a specialty vehicle manufacturer acquired by PositiveID in December 2015, has delivered more than 400 mobile labs to customers around the world.
The largest and fastest growing aspect of ENG’s business over the last decade has been its mobile labs segment, which includes government and corporate laboratories for chemical, biological, nuclear, radiological and explosives testing in the field. ENG has delivered more than 100 mobile labs for the U.S. Army, plus numerous laboratories to other government agencies including U.S. Customs and Border Protection, U.S. Navy, U.S. Air Force, prominent national laboratories, and nine of the 10 regions of the Environmental Protection Agency.
“ENG is an industry leader in designing mobile labs for chemical and biological detection, monitoring, and analysis,” stated William J. Caragol, Chairman and Chief Executive Officer of PositiveID. “This mobile lab, developed under a large contract that will generate significant revenue for PositiveID during the second quarter and keep us on track to reach our revenue goals for 2016, is the latest example of our robust capabilities, expertise and best-in-class products.”
In addition to mobile labs, ENG has delivered more than 1,200 other technical vehicle systems. These include communications/command centers, broadcast news vehicles, radio frequency monitoring, infrared monitoring and video communications vehicle systems, plus a wide range of mobile systems for emergency preparedness and threat response.
Q1 Revenue of $1.7M (+1600.0% Y/Y).
http://seekingalpha.com/news/3183853-positiveid-reports-q1-results
PositiveID Corporation, (OTCQB: PSID, "PositiveID"), is a life sciences company focused on developing and commercializing innovative products for biological testing, detection, and diagnostics. The company's flagship product, the Firefly Dx, is a real-time, handheld molecular diagnostic currently under development that utilizes a proprietary polymerase chain reaction (PCR) automated pathogen detection system, which can be used in the field for biological threat and infectious disease detection without the use of bulky lab equipment. Founded in 2001, PositiveID has amassed an impressive list of customers and partners, including The Department of Homeland Security, NASA, and the US Department of Defense, among others. With a product portfolio bolstered by the December 2015 acquisitions of E-N-G Mobile Systems (E-N-G) and Thermomedics, PositiveID appears to be off to a strong start to FY2016. The company reported 1Q16 results on May 17, 2016, with highlights as follows:
Revenues rose to $1.7mn, with growth coming primarily from momentum in the mobile labs business at E-N-G
PositiveID also appeared to benefit from scale, as 1Q16 operating losses narrowed from 1Q15
PSID issued a strong outlook, calling for continued growth throughout the year and a push towards reaching cash flow breakeven by FY17E
Highlights of note are as follows:
Acquisitions drive growth in 1Q16; tracking well with top line guidance for FY16E
PositiveID reported strong top line results in 1Q16, with revenues rising to $1.7mn from $0.1mn in 1Q15. The results were driven primarily by the acquisition of E-N-G, which experienced growth in its mobile labs business. We note that the company appears to be well on its way to meeting its FY16 guidance of $5mn - $6mn, and are maintaining our 2016E revenue estimate of $6.0mn, which would represent more than 100% revenues growth over 2015 revenues of $2.9mn.
Positive Outlook for 2016
PositiveID management issued a positive outlook for the remainder of 2016. In the company's 1Q16 earnings release CEO William Caragol stated that he believes PositiveID's "top line will continue to improve throughout 2016" and that the company can "make additional strides to improve gross margins and meet our goal of achieving cash flow positive." Although we acknowledge the inherent variability from quarter to quarter in PSID's business lines, we are encouraged by this commentary and the degree of growth in 1Q16. Indeed, the combined company's results showed healthy double-digit growth even when comparing to 1Q15 pro forma, as-if-consolidated revenues of $1.4mn. Moreover, the company appears to have continuing strong momentum in its mobile labs business, as PositiveID noted in April that it had shipped a $700,000+ 40-foot, BSL-3 compliant mobile laboratory, which will be recognized during 2Q16.
News : May 31, 2016 PositiveID Adds Benedikt von Braunmuhl to its Board of Advisors
Mr. von Braunmuhl has more than 20 years of experience with global healthcare companies, and will assist the Company’s efforts to commercialize Firefly Dx to detect Zika and other pathogens
DELRAY BEACH, Fla., May 31, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has added international healthcare and business development executive Benedikt von Braunmühl to its Board of Advisors.
Von Braunmühl is currently Chairman of the Board of Directors of PathoQuest, a next generation molecular diagnostics company with a unique approach in infectious diseases diagnostics. In addition, he acts as advisor of the healthcare practice group at Clairfield International, a mergers and acquisitions advisory firm for global mid-market transactions with 39 offices in 23 countries. He has held several high-profile healthcare consulting and advisory roles for companies across the globe supporting geographic expansion, business development, and mergers and acquisitions projects. Von Braunmühl previously was Senior Vice President - Global Commercial Operations of Qiagen NV, a leading European biotechnology company active in molecular diagnostics and life science markets.
“We are honored to add Benedikt to our Board of Advisors to raise awareness of our product offerings and our technical and scientific expertise among potential partners,” said William J. Caragol, Chairman and CEO of PositiveID. “We believe his strategic insights and broad industry relationships, which align closely with our business, will be valuable in helping us reach the next stage in our growth.”
Mr. von Braunmühl started his 25-year healthcare career at AstaMedica and has held various marketing and sales positions in the healthcare industry as well as in investment banking. He holds a Bachelor Degree in Business Administration from the Graduate School of Business Administration in Zurich, Switzerland.
The zika virus shows ever since its dangerous aspect as well as its potential to become a pandemic
Raad Shakir, president of the World Federation of Neurology, in his speech at the Second Congress of the European Academy of Neurology, which is taking place in Copenhagen, Denmark. "The zika virus shows ever since its dangerous aspect as well as its potential to become a pandemic," said the scientist, noting that Europe needs to prepare for it.
60 countries report Zika transmission
According to latest WHO figures, as of 18 May 2016, 60 countries and territories report continuing mosquito-born Zika transmission. Ten countries, among them Germany and France, have reported person-to-person transmission of Zika virus, most probably via a sexual route. Microcephaly and other fetal malformations potentially associated with Zika virus infection or suggestive of congenital infection have been reported in eight countries or territories. Thirteen countries and territories worldwide have reported an increased incidence of Guillain-Barré syndrome and/or laboratory confirmation of Zika virus infection among GBS cases.
Europe needs to be prepared for Zika virus epidemic, experts say
https://www.sciencedaily.com/releases/2016/05/160530101142.htm
18 infected by Zika virus in Virginia, 4 in DC, 17 in Maryland
http://wjla.com/news/local/18-infected-by-zika-virus-in-virginia-4-in-dc-17-in-maryland
CDC's Frieden makes stern Zika warning
As the U.S. congress left for a two-week break without passing a plan to combat the Zika virus, CDC Director Dr. Tom Frieden says that the U.S. needs a robust response sooner than later.
http://edition.cnn.com/videos/health/2016/05/27/cdc-zika-tom-frieden-frustration-epidemic-sot.cnn/video/playlists/zika/
SELLERS INCREASED BY 207.78% THEIR SHORTS
http://hintsnewsnetwork.com/positiveid-corporati-otcmktspsid-sellers-increased-by-207-78-their-shorts/86513/
Zika virus raises international travel concerns
http://www.wtvm.com/story/32090216/zika-virus-raises-international-travel-concerns
Zika virus is being mishandled like Ebola epidemic warns global
http://www.dailymail.co.uk/sport/olympics_2016/article-3614511/Zika-virus-mishandled-like-Ebola-epidemic-warns-global-health-expert-ahead-Olympics.html
Zika virus expert warns tourists to 'think twice' about trips to Disney World
http://www.independent.co.uk/news/world/americas/zika-virus-travel-united-states-america-a7054586.html
Georgia health officials report sexually transmitted case of Zika virus
http://www.foxnews.com/health/2016/05/27/georgia-health-officials-report-sexually-transmitted-case-zika-virus.html
Two more people in Alabama diagnosed with Zika virus
http://www.al.com/news/index.ssf/2016/05/two_more_people_in_alabama_dia.html
“Last year the disease was detected in the Americas, where it is spreading explosively,” Margaret Chan, the WHO director general, said at a special briefing in Geneva. It was “deeply concerning” that the virus had now been detected in 23 countries in the Americas, she added.
One WHO scientist estimated there could be 3-4m Zika infections in the Americas over the next year.
http://www.theguardian.com/world/2016/jan/28/zika-virus-spreading-explosively-says-world-health-organisation
PositiveID’s E-N-G Mobile Systems Ships Mobile Lab in Excess of $700,000 to Customer
DELRAY BEACH, Fla., April 25, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its E-N-G Mobile Systems (“ENG”) subsidiary has shipped a 40-foot BSL-3 compliant mobile laboratory valued in excess of $700,000. Due to the nature and location of the mobile lab, the customer is being kept confidential. Since its inception, ENG, a specialty vehicle manufacturer acquired by PositiveID in December 2015, has delivered more than 400 mobile labs to customers around the world.
“ENG is an industry leader in designing mobile labs for chemical and biological detection, monitoring, and analysis,” stated William J. Caragol, Chairman and Chief Executive Officer of PositiveID. “This mobile lab, developed under a large contract that will generate significant revenue for PositiveID during the second quarter and keep us on track to reach our revenue goals for 2016, is the latest example of our robust capabilities, expertise and best-in-class products.”
http://www.otcmarkets.com/stock/PSID/news/PositiveID-rsquo-s-E-N-G-Mobile-Systems-Ships-Mobile-Lab-in-Excess-of--700-000-to-Customer?id=130037&b=y
Q1 Revenue of $1.7M (+1600.0% Y/Y).
http://seekingalpha.com/news/3183853-positiveid-reports-q1-results
Jun 1, 2016
2:30 PM ET
2016 Marcum MicroCap Conference
View Presentation
http://files.shareholder.com/downloads/ABEA-3Y7P8E/2134986863x0x893951/07DE11E8-BCC5-4FC2-938D-1C7E65479E4B/PSID_presentation_Marcum_June_1_2016.pdf
As summer approaches, fears of the fever-causing Zika virus mount globally.
According to the Wall Street Journal, the scope and severity of prenatal damage from the Zika virus are much worse than expected. The paper reports, “Scans, imaging and autopsies show that Zika eats away at the fetal brain. It shrinks or destroys lobes that control thought, vision and other basic functions. It prevents part of the brain not yet formed from developing.”
One company seeking to aid officials in their quest to quickly identify Zika at the source is PositiveID Corp. (OTCQB: PSID). Working with assay partner GenArraytion, PSID has successfully detected the Zika virus on its proprietary Firefly Dx prototype system.
Working with assay partner GenArraytion, PSID has news of the successful detection of Zika could propel shares of PSID significantly higher in the coming weeks and months.
http://www.redchip.com/articles/594/positiveid-successfully-detects-the-zika-virus-on-its-firefly-dx-prototype-system
PositiveID Corporation (PSID) is at the forefront of developing a unique bio detection device, its Firefly Dx handheld diagnostic system, which can be used in the field to identify threats such as Zika, dengue fever, SARS, Ebola, influenza, agricultural disease, etc., at the point of need. Also, with the recent acquisition of two established, revenue generating businesses, E-N-G Mobile Systems, Inc. and Thermomedics, Inc., PSID is poised to dominate this niche of the biotech realm.
PSID developed its M-BAND product, with over $30 million of contract funding from the Department of Homeland Security, to autonomously and continuously analyze the air for weaponized pathogens such as Anthrax and other biological threats in real time, wirelessly with all programmed field instruments.
http://finance.yahoo.com/news/zika-virus-potential-effect-olympics-140000798.html
WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
COMPANIES MENTIONED: PositiveID Corporation (PSID); Inovio Pharmaceuticals, Inc. (INO);Chimerix, Inc. (CMRX); BioCryst Pharmaceuticals, Inc. (BCRX); Intrexon Corporation(NYSE:XON).
http://wealthyventurecapitalist.com/2016/02/03/who-declares-zika-a-health-emergency-of-international-concern-5-companies-developing-technologies-in-the-fight-against-the-epidemic/
bid 0.0133 x ask 0.014
The company reported 1Q16 results on May 17, 2016, with highlights as follows:
Revenues rose to $1.7mn, with growth coming primarily from momentum in the mobile labs business at E-N-G
PositiveID also appeared to benefit from scale, as 1Q16 operating losses narrowed from 1Q15
PSID issued a strong outlook, calling for continued growth throughout the year and a push towards reaching cash flow breakeven by FY17E
Highlights of note are as follows:
Acquisitions drive growth in 1Q16; tracking well with top line guidance for FY16E
PositiveID reported strong top line results in 1Q16, with revenues rising to $1.7mn from $0.1mn in 1Q15. The results were driven primarily by the acquisition of E-N-G, which experienced growth in its mobile labs business. We note that the company appears to be well on its way to meeting its FY16 guidance of $5mn - $6mn, and are maintaining our 2016E revenue estimate of $6.0mn, which would represent more than 100% revenues growth over 2015 revenues of $2.9mn.
Positive Outlook for 2016
PositiveID management issued a positive outlook for the remainder of 2016. In the company's 1Q16 earnings release CEO William Caragol stated that he believes PositiveID's "top line will continue to improve throughout 2016" and that the company can "make additional strides to improve gross margins and meet our goal of achieving cash flow positive." Although we acknowledge the inherent variability from quarter to quarter in PSID's business lines, we are encouraged by this commentary and the degree of growth in 1Q16. Indeed, the combined company's results showed healthy double-digit growth even when comparing to 1Q15 pro forma, as-if-consolidated revenues of $1.4mn. Moreover, the company appears to have continuing strong momentum in its mobile labs business, as PositiveID noted in April that it had shipped a $700,000+ 40-foot, BSL-3 compliant mobile laboratory, which will be recognized during 2Q16.